Robust Counterfactual Impact Evaluation
Also known as: Robust CIE, Sensitivity-checked CIE, Multi-method counterfactual evaluation, Robustness-validated impact evaluation
Robust Counterfactual Impact Evaluation (Robust CIE) strengthens causal impact estimates by combining multiple quasi-experimental estimators, placebo tests, and formal sensitivity analyses. Rather than relying on a single method, it cross-validates findings across approaches — such as matching, difference-in-differences, and regression discontinuity — to ensure that conclusions do not depend on any single methodological choice.
Key highlights
- Cross-validation across methods substantially reduces the risk that findings are artifacts of a single design choice or violated assumption.
- Placebo and falsification tests provide transparent, interpretable evidence of identification validity.
- Sensitivity bounds (Gamma analysis) give stakeholders a concrete measure of how vulnerable the conclusion is to unmeasured confounding.
- Aligns with best-practice standards required by the European Commission and other major funding bodies for programme evaluation.
- Improves credibility in peer review and public reporting by demonstrating that the result is not method-specific.
Intuition
This section is available to Pro members. Upgrade to Pro
How it works
This section is available to Pro members. Upgrade to Pro
When to use it
Use Robust CIE when the stakes of a policy or programme evaluation are high — for example, EU Structural Fund assessments, national public programme evaluations, or regulatory impact analyses — and a single-method estimate would be insufficient to convince policymakers or reviewers. It is appropriate when you have observational panel or cross-sectional data with a credible comparison group, and when multiple quasi-experimental designs are feasible given the data structure. Do not use it when data are too scarce to support multiple estimators, or when a randomised controlled trial is available and provides direct experimental evidence without the need for robustness scaffolding.
Strengths & limitations
- Cross-validation across methods substantially reduces the risk that findings are artifacts of a single design choice or violated assumption.
- Placebo and falsification tests provide transparent, interpretable evidence of identification validity.
- Sensitivity bounds (Gamma analysis) give stakeholders a concrete measure of how vulnerable the conclusion is to unmeasured confounding.
- Aligns with best-practice standards required by the European Commission and other major funding bodies for programme evaluation.
- Improves credibility in peer review and public reporting by demonstrating that the result is not method-specific.
- Computationally and analytically demanding: requires implementing, validating, and reporting several estimators rather than one.
- If different estimators identify different sub-populations (e.g., local vs. average treatment effects), apparent discordance may reflect heterogeneity rather than failure of assumptions.
- Placebo tests require pre-treatment data or genuine control units, which may not always be available.
- Sensitivity analysis bounds indicate vulnerability to confounding but cannot prove that no confounding is present.
Common pitfalls
This section is available to Pro members. Upgrade to Pro
Applications
This section is available to Pro members. Upgrade to Pro
Frequently asked
How many methods should I use for a robust evaluation?
At least two or three methods with meaningfully different identifying assumptions. For example, combining propensity score matching (selection on observables) with difference-in-differences (parallel trends) and a placebo test covers distinct threat types. More methods are valuable only if data support them credibly.
What does Rosenbaum's Gamma sensitivity parameter tell me?
Gamma measures the maximum odds ratio by which a hidden confounder could make matched units differ in their probability of treatment. A Gamma of 1.5 means an unmeasured variable making one unit 1.5 times more likely to be treated would be needed to nullify the result. Larger Gamma values indicate greater robustness to hidden bias.
If estimates from different methods diverge, which one should I report?
Do not simply pick the one you prefer. Diagnose why they diverge: differences in the targeted estimand (ATT vs. ATE), sample restrictions, or violated assumptions. Report all estimates transparently, explain likely sources of divergence, and draw conclusions with appropriate uncertainty.
Is Robust CIE required for EU Structural Fund evaluations?
EU evaluation guidance strongly recommends counterfactual methods and robustness validation. While no single protocol is formally mandated, the European Commission's Better Regulation guidelines and ex-post evaluation standards effectively require demonstrating robustness through multiple methods or sensitivity checks.
Can I apply Robust CIE with a small sample?
Small samples are problematic because each individual estimator already loses statistical power, and running multiple methods compounds this. Below roughly 100 treated units, it is better to focus on one well-powered design with careful diagnostics than to spread thin data across several underpowered estimators.
Sources
- 1.Bia, M., Flores, C. A., Flores-Lagunes, A., & Mattei, A. (2014). A Stata package for the application of semiparametric estimators of dose–response functions. Stata Journal, 14(3), 580–604.
- 2.Ferrara, A. R., McCann, P., Pellegrini, G., Stelder, D., & Terribile, F. (2017). Assessing the impacts of Cohesion Policy on EU regions: A non-parametric analysis on interventions with multiple treatment intensities. Environment and Planning C: Politics and Space, 35(8), 1467–1487.
You have read it. What now?
Cite this page
ScholarGate. (2026, June 3). Robust Counterfactual Impact Evaluation. ScholarGate. https://scholargate.app/causal-inference/robust-counterfactual-impact-evaluation